BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce today that it has filed a final short form prospectus (the "Final Prospectus") with the securities regulatory authorities in the provinces of British
2026-09-11 7:45 PM EDT | BetterLife Pharma Inc.
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte Ne
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-11 9:00 AM EDT | Phio Pharmaceuticals Corp.
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026. The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at
Biotechnology, Pharmaceuticals
2026-09-09 4:30 PM EDT | InMed Pharmaceuticals
Herbal Dispatch Provides Update on Gold Royalty Interest in Artemis Gold's Blackwater Mine
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, today provided an update on a gold royalty interest held by the Company on mineral claims forming part of the Blackwater mine in central British Columbia. OVERVIEW OF THE ROYALTY Herbal Dispatch holds a royalty interest (the "Ro
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-09-09 1:01 AM EDT | Herbal Dispatch Inc.
Maxwell Biosciences Receives FDA Qualified Infectious Disease Product (QIDP) Designation for All-Cause Bacterial and Fungal Pneumonia
Austin, Texas--(Newsfile Corp. - September 8, 2026) - Maxwell Biosciences, a biotechnology company developing a new class of immune-inspired anti-infective therapeutics, today announced that on May 5, 2026, the U.S. Food and Drug Administration (FDA) granted Qualified Infectious Disease Product (QIDP) designation to MXB-22,510-SC, Maxwell's investigational parenteral injectable drug candidate for the treatment of community-acquired pneumonia (CAP) and hospital-acquired (HAP) or ventilator-ass
Biotechnology, Pharmaceuticals
2026-09-08 9:00 AM EDT | Maxwell Biosciences, Inc.
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Encinitas, California--(Newsfile Corp. - September 8, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the appointment of Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs. Mr. Lane has over 20 years of experience in ophthalmic drug development, clinical development and operations and regulatory strategy across Phase 1 through Phase 4 clinical trials. "Keith has substantial experience supporting U.
Biotechnology, Pharmaceuticals
2026-09-08 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Custom Health Completes Acquisition of Spencer Health Solutions, Bringing In-Home Medication Dispensing Technology Fully In-House
Effective September 4, 2026, Custom Health has completed its previously announced acquisition of Spencer Health Solutions, developer of the spencer® smart medication dispenser and in-home monitoring platform, giving the Company full ownership of the spencer® technology, intellectual property, and product roadmap. Spencer now operates as a wholly owned subsidiary of Custom Health, eliminating third-party support, infrastructure, and device costs previously incu
Technology, Pharmaceuticals, Health
2026-09-08 6:00 AM EDT | Custom Health Holdings Inc.
Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
Montreal, Quebec--(Newsfile Corp. - September 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to provide a letter to shareholders from President and Chief Executive Officer Dr. Amie Phinney outlining recent corporate progress, strategic priorities and the Company'
Biotechnology, Pharmaceuticals, Health
2026-09-08 3:15 AM EDT | Defence Therapeutics Inc.
Defence Therapeutics Provides Updates on Sharing Agreement
Montreal, Quebec--(Newsfile Corp. - September 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to provide an update on its sharing agreement dated March 6, 2026 (the "Sharing Agreement") with Sorbie Bornholm LP ("SBLP") previously described in the Company's news releases of March 9 and February 27, 202
Biotechnology, Pharmaceuticals, Health
2026-09-04 6:00 PM EDT | Defence Therapeutics Inc.
Nextleaf Solutions Reports Fiscal Q3 2026 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf" or the "Company"), a multi-patented Canadian cannabis processor, released its financial results for the third quarter ended June 30, 2026. The quarter reflected sequential improvement in net revenue and a significant reduction in excise taxes, supported by a broadened product mix including non-excisable bulk sales and tolling services. Net r
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-09-03 5:01 PM EDT | Nextleaf Solutions Ltd.
PerkinElmer Completes Acquisition of SimoTech
Shelton, Connecticut--(Newsfile Corp. - September 3, 2026) - PerkinElmer, a global leader in analytical solutions and specialized services for the life sciences, applied, and food markets, today announced the completion of its acquisition of SimoTech, a trusted provider of manufacturing automation and GMP IT solutions to the life sciences industry, following the company's announcement of the signed transaction on August 11, 2026. Founded in 2011 and headquartered in Cork, Ireland, Simo
2026-09-03 8:45 AM EDT | PerkinElmer
BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange (TASE) and to become dual-listed for trade on both the Nasdaq and TASE markets. BioHarvest expects its shares to begin trading on the TASE on September 8, 2026. Dr Zak
Biotechnology, Pharmaceuticals, Health
2026-09-03 7:00 AM EDT | BioHarvest Sciences Inc.
TempraMed Signs Letter of Intent with CPO Greece for Exclusive Distribution of VIVI Products in Greece
Highlights: LOI with CPO Greece includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Greece, subject to a definitive agreement. Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity. Transfer pricing and the first-year minimum unit commitment will be negotiated an
Technology, Biotechnology, Pharmaceuticals, Health
2026-09-01 6:45 AM EDT | TempraMed Technologies Ltd.
Herbal Dispatch Reports 2026 Second Quarter Financial Results
Vancouver, British Columbia--(Newsfile Corp. - September 1, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, today reported financial results for the three and six months ended June 30, 2026, highlighted by strong growth in its medical and international businesses, a 74% increase in quarterly gross profit, and an expansion in gross margin to 28.8%
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-09-01 12:14 AM EDT | Herbal Dispatch Inc.
BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of Charles Duncan, PhD as Director and Chair of the Audit Committee. Dr. Duncan is a biotechnology strategist, board director and former top-ranked Wall Street biotechnology anal
2026-08-31 8:00 AM EDT | BetterLife Pharma Inc.
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
Montreal, Quebec--(Newsfile Corp. - August 31, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the expansion of its radiopharmaceutical development program to evaluate alpha-emitting and beta-emitting radioisotopes. This expansion is to broaden the capabi
Biotechnology, Pharmaceuticals, Health
2026-08-31 3:15 AM EDT | Defence Therapeutics Inc.
Theralase(R) Releases Q2 2026 Financial Statements
Toronto, Ontario--(Newsfile Corp. - August 28, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, has released the Company's unaudited interim consolidated financial statements for the six-month period ended Jun
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-28 4:36 PM EDT | Theralase Technologies Inc.
Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter
Gaithersburg, Maryland--(Newsfile Corp. - August 28, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) (the "Company" or "Shuttle"), today announced that the Company is not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) as a result of its failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 with the Securities and Exchange Commission by the required due date. The Co
2026-08-28 4:05 PM EDT | Shuttle Pharmaceuticals Holdings Inc.
BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
Vancouver, British Columbia--(Newsfile Corp. - August 28, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce today that it has priced its previously announced public offering (the "Offering") of common shares of the Company ("Commo
2026-08-28 8:00 AM EDT | BetterLife Pharma Inc.
NuGen Announces Filing of Corrective Disclosure Pursuant to OSC Review
Toronto, Ontario--(Newsfile Corp. - August 27, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") announces that further to the review by the Ontario Securities Commission ("OSC") of the Company's continuous disclosure, the Company has made corrective disclosure with respect to the following: the Company has included in its recently filed management information circular dated August 17, 2026 (the "Circul
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-27 5:30 PM EDT | NuGen Medical Devices Inc.